Date: 2012-05-08
Type of information: Co-promotion agreement
Compound: EYLEA® (aflibercept)
Company: Bayer (Germany) Regeneron Pharmaceuticals (USA) Santen (Japan)
Therapeutic area: Ophtalmological diseases
Type agreement: co-promotion
Action mechanism: VEGF Trap-Eye is a fully human, soluble VEGF receptor fusion protein that binds all forms of VEGF-A along with another vascular growth factor, the Placental Growth Factor (PlGF). VEGF Trap-Eye is a specific and highly potent blocker of VEGF-A and PlGF that has been demonstrated in preclinical models to bind these growth factors with greater affinity than their natural receptors.
Disease: neovascular age-related macular degeneration (wet AMD)
Details: Regeneron Pharmaceuticals and Bayer HealthCare have announced that Bayer\'s Japanese subsidiary, Bayer Yakuhin, and Santen Pharmaceutical entered into a co-promotion agreement for EYLEA® (aflibercept) Injection in Japan. As previously announced, Bayer Yakuhin has submitted an application for marketing authorization to the Ministry of Health, Labor and Welfare (MHLW) for EYLEA® for the treatment of neovascular age-related macular degeneration (wet AMD). Bayer and Regeneron have also amended their existing global license and collaboration agreement for EYLEA to convert the 50/50 profit share for Japan into a royalty arrangement that approximates the economics of the profit split. In certain specified circumstances, the royalty may revert to a profit share arrangement.
Financial terms:
Latest news:
